Due to its modularity, the SMARTag conjugation platform can be broadly applied to various disease contexts. The platform also leverages ease of analytics and a critical ability to deliver efficacy coupled with good tolerability.
The choice of potential technology transfer partners can be bewildering. Mike Valazza, vice president, global business development, shares some of the factors that should be considered when making this decision.
As the product development program progresses to the Phase 3 clinical stage, formulation development is required to ensure drug product quality and stability during manufacturing, storage, and clinical administration.